Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP001 in Secondary Hyperparathyroidism in Hemodialysis Patients
NCT01922843Phase 2Completed
- Sponsor
- Deltanoid Pharmaceuticals
- Start
- Sep 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DP-001 in secondary hyperparathyroidism (SHPT), sponsored by Deltanoid Pharmaceuticals. Started Sep 2013; status: completed.
02
Drugs
DP-001
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01922843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01922843.